PHIGENIX
`PHIGENIX
`Exhibit 1032
`Exhibit 1032
`
`
`
`
`
`

`
`
`
`MaI<i:ng Cancer History”
`
`CURRICULUM VITAE
`
`Michael G. Rosenblum, Ph.D.
`
`PRESENT TITLE AND AFFILIATION
`
`Primary Appointment
`
`Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D.
`Anderson Cancer Center, Houston, TX
`
`Head, Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental
`Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX
`
`Dual/Joint/Adjunct Appointment
`N/A
`
`CITIZENSHIP
`United States
`
`OFFICE ADDRESS
`M.D. Anderson Cancer Center
`1901 East Road
`Unit Number: 1950
`
`Houston, TX 77054
`Room Number: 3SCR4.3418
`Phone: 713-792-3554
`
`Email: mrosenb|@mdanderson.org
`
`EDUCATION
`
`Degree-Granting Education
`University of South Carolina, Columbia, SC, BS, 1972, Chemistry
`
`Medical University of South Carolina, Charleston, SC, MS, 1974, Pharmacology
`
`University of Arizona College ofMedicine, Tucson, AZ, Ph.D., 1978, Pharmacology
`
`Postgraduate Training
`Project Investigator, MD Anderson Cancer Center, Houston, TX, 12/1978-6/1980
`
`Research Associate, MD Anderson Cancer Center, Houston, TX, 6/1980-9/1981
`
`CREDENTIALS
`Board Certification
`N/A
`
`Licensu res
`Active
`
`PHIGENIX
`
`Exhibit 1032-01
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`N/A
`
`Inactive
`N/A
`
`EXPERIENCEISERVICE
`
`Academic Appointments
`Assistant Professor, Department of Clinical Immunology and Biological Therapy, M.D. Anderson
`Cancer Center, Houston, TX, 1981-1987
`
`Tenure Awarded 1985
`
`Associate Professor, Department of Bioimmunotherapy, M.D. Anderson Cancer Center, Houston,
`TX, 1988-1997
`
`Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D.
`Anderson Cancer Center, Houston, TX, 1997-present
`
`Administrative AppointmentslResponsibilities
`Head, lmmunopharmacology and Targeted Therapy Laboratory, Department of Experimental
`Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX,
`1984-present
`
`Director of Research Development, Department of Experimental Therapeutics, M.D. Anderson
`Cancer Center, Houston, TX, 9/2008-2013
`
`Other AppointmentsIResponsibi|ities
`Associate Pharmacologist, M.D. Anderson Cancer Center, Houston, TX, 1986-1999
`
`Invited Study Section Member (Cancer), Tobacco—Re|ated Disease Research Program (TRDRP),
`California and Colorado, 5/2000-5/2003
`
`Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston,
`TX, 2001-2010
`
`Endowed Positions
`N/A
`
`Consultantships
`ProNeuron (Formerly lgen, |nc.), Bethesda, Advisory Board Member, 12/1993-1997
`
`Biogen, Inc, Cambridge, Advisory Board Member, 8/1994-1996
`
`Novopharm Biotech, Inc, Winnipeg, Advisory Board Member, 8/1995-2002
`
`Caprion Pharmaceuticals, Montreal, Quebec, Canada, Member, Scientific and Clinical Advisory
`Board, 2006-2010
`
`Targa Therapeutics, Houston, TX, Founder and Chief Scientific Consultant, 1/2006-12/2010
`
`Thallion Pharmaceuticals, Montreal, Canada, Consultant, CAB, and SAB Member,
`1/2010-12/2010
`
`Kyto Pharmaceuticals, Toronto, Canada, Consultant, 1/2010-12/2010
`
`Savoy Pharmaceuticals, Consultant, 1/2011-1/2012
`
`RCT Therapeutics, Inc, 2012-2013
`
`Military or Other Governmental Service
`N/A
`
`Institutional Committee Activities
`
`Member, Research Committee, 1983-1989
`
`Page 2 of 31
`
`PHIGENIX
`
`Exhibit 1032-02
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Member, Investigational Drug Committee, 1983-1992
`
`Member, Biological Response Modifier Committee, Member, 1986-1990
`
`Member, Pharmacy and Therapeutics Committee, 1989-1992
`
`Member, Animal Care and Use Committee, 1990-1993
`
`Member, Education Subcommittee Faculty Achievement Award, 1992
`
`Elected Member, Faculty Senate, 1994-1998
`
`Member, Institutional Biosafety Committee, 1994-1999
`
`Member, Clinical Research Committee, 1995-1999
`
`Elected Member, Immunology Program Steering Committee, 1996-1998
`
`Elected Member, Faculty Senate Executive Committee, 1996-1998
`
`Member, GSBS Admissions Committee for Immunology, 1996-2002
`
`Chair, Faculty Senate Education Committee, 1996-2006
`
`Co—Chair, Institutional Ground Rounds Organization Committee, 1996-present
`
`Member, Research Council, 1997-1998
`
`Member, Faculty Senate/Division ofMedicine Liaison Committee, 1997-1998
`
`Member, Promotion and Tenure Task Force, 1997-1999
`
`Co—Chair, CME Steering Committee, 1997-2002
`
`Member, Postdoctoral Program Advisory Committee, 1998-2002
`
`Member, Faculty Senate IS Sub—Committee, 1998
`
`Member, Molecular Targeting Working Group Focusing on Aerodigestive Cancers, 2000-2001
`
`Member, Clinical & Translational Research Center (CTRC) Review Committee, 2001-2002
`
`Member, Oversight Committee of the Cancer Therapeutics Discovery Program, 2001-2003
`
`Member, Radioactive Drug Research Committee, 2001-2004
`
`Member, Education Council, 2001-2007
`
`Member, Institutional Cancer Therapeutics Development Program, 2002-present
`
`Member, MDACC “Technology Champions” Group, 2002-2012
`
`Elected Representative, Faculty Senate — Experimental Therapeutics Department, 2003-2011
`
`Elected Member, Faculty Senate Executive Committee, 2005-2011
`
`Member, MDACC Conflict of Interest Committee, 2005—present
`
`Vice—Chair, MDACC Conflict of Interest Committee, 2007-2009
`
`Chair, MDACC Conflict of Interest Committee, 2009-2011
`
`Past Chair, MDACC Conflict of Interest Committee, 2011—present
`
`Member, MDACC Technology Review Committee, 2010-2013
`
`Chair, Faculty Senate Faculty Achievement Awards Committee, 2011-2014
`
`Member, Executive Committee ofthe Science Faculty, 2007-2012
`
`Member, Experimental Therapeutics Management Team, 2008-2013
`
`Page 3 of 31
`
`PHIGENIX
`
`Exhibit 1032-03
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Member, ET Seminar Series Committee, 2008—present
`
`Chair, New Perspectives in Targeted Biomolecules Seminar Series(ET) 2009-2012
`
`Chair, MDACC Blue Ribbon Panel on Conflict of Interest Policy Review, 2011-2012
`
`Chair, MDACC Blue Ribbon Panel on IACUC Policies/Enforcement, 2013
`
`Member, MDACC Bridge Funding Committee, 2011-present
`
`Member, Executive Research Compliance Committee, 2011-present
`
`MDACC Senior Officer for Research Integrity, 9/2013—present
`
`HONORS AND AWARDS
`N/A
`
`RESEARCH
`Grants and Contracts
`Funded
`
`Co-Principal Investigator, 0.12 months, Development of Therapeutic Agents Targeting the
`FN14 Receptorfor TWEAK, R01 NS55126, NIH/NCI, 12/1/2009-11/30/2012, NCE, $83,116
`($41 ,558/year)
`
`Principal Investigator, 2.88 months, Monoclonal Antibody Delivery Systems,C|ayton
`Foundation for Research, 12/1987-Present $500,000 ($500,000/year)
`
`Principal Investigator, 1.2 months, Application of Photochemical lnternalization to optimize
`delivery of VEGF121-rGe| to the vasculature of invasive solid tumors, UT MDACC Sister
`Institution Network Fund, 9/1/2012-8/31/2014, $100,000 ($50,000/year)
`
`Co-Investigator, 0.48 months, GrB—TWEAK: A Potential Novel Biologic for NSCLC Therapy,
`DOD Lung Cancer Idea Award, 10/1/2014-9/30/2015, $33,869/year
`
`Pending
`Co-Investigator, 0.48 months, Development of Fn—14 Targeted, GrB—Based Agents for
`NSCLC Therapy, NIH/NCI, PI - Winkles, 7/1/2014-6/30/2015 ($30,794/year)
`
`Other
`N/A
`
`Completed
`Co-Investigator, Correlated clinical-laboratory Phase I trials, UO1 CA62461—06, NIH/NCI,
`2/1/1998-1/31/2003, $1,671,168 ($334,234/year)
`
`Co-Investigator, Bioimmunotherapy training grant, 1P32CA72321—1A1, American Institute for
`Cancer Research (AICR), 9/30/1998-7/31/2002, $961,655 ($192,331/year)
`
`Principal Investigator, Molecular engineering to retarget human cytokines, DAMD17—99—1-
`9259-2 BC980048, Department of Defense (DOD), 7/1/1999-6/30/2002, $263,461
`($65,865/year)
`
`Co-Investigator, New agents for Taxol-resistant ovarian carcinoma, OC990052, DOD Ovarian
`Cancer Research Program, 10/20/1999-10/19/2002, $450,016 ($11,252/year)
`
`Principal Investigator, Evaluation of novel agents which targets neovasculature of bladder
`tumors, N/A, Developmental Research Award Bladder Cancer SPORE Grant,
`12/1/2001-11/30/2002, $40,000 ($40,000/year)
`
`Principal Investigator, 1.2 months, Protein fermentation and manufacturing, Clayton
`Foundation for Research, 9/1/2003-12/31/2012, $115,000 ($115,000/year)
`
`Page 4 of 31
`
`PHIGENIX
`
`Exhibit 1032-04
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Co—Principa| Investigator, BLyS—Ge|onin: A Targeted Therapeutics for CLL, Leukemia and
`Lymphoma Society, 10/1/2006-9/30/2009, $180,000, NCE 2009-2011.
`
`Principal Investigator, Evaluation of novel agents which target neovasculature of breast
`tumors, BC010025, Department of Defense (DOD), 4/1/2002-3/31/2006, $637,530
`($127,506/year)
`
`Principal Investigator, Pre—|ND Studies of Novel, Recombinant Therapeutic Agents,Targa
`Therapeutics Corporation, 10/11/2005-10/11/2007, $120,000 ($60,000/year)
`
`Not Funded
`
`Co—|nvestigator, Inhibition of Breast Cancer Metastatsis by Targeting the Pre—Metastatic
`Niche, MDACC, PI — Khalid Mohamedali, 2006-2007
`
`Co—|nvestigator, Role of VEGF and VEGFR on Osteoclastogenesis and Prostate Tumor
`Growth in Bone, Bone Disease Program of Texas, Pl — Khalid Mohamedali, 2006-2007
`
`Co—|nvestigator, Targeting VEGF Receptors in the Prevention of Breast Cancer Metastasis,
`Department of Defense (DOD), Pl — Khalid Mohamedali, 2006-2009
`
`Co—|nvestigator, VEGF and BEGF Receptors in Osteoclastogenesis and Prostate Tumor
`Growth in Bone, Department of Defense (DOD), Pl — Khalid Mohamedali, 2006-2009
`
`Co—Principa| Investigator, 10%, BLyS—Ge|onin: A Targeted Therapeutics for Chronic
`Lymphocytic Leukemia, 6234-07, Translational Research Program, Pl — Varsha Gandhi,
`10/2006-10/2009
`
`Co—|nvestigator, Effect of VEGF121/rGe| on Multiple Myeloma Homing and Osteoclast
`Precursor Cell Recruitment, MDACC, Pl — Khalid Mohamedali, 2008-2009
`
`Co—|nvestigator, Inhibition of Breast Cancer Metastasis to Bone by Targeting the Pre—Metastic
`Niche, Bone Disease Program of Texas, Pl — Khalid Mohamedali, 2008-2009
`
`Consultant, Fullerene lmmunoconjugates for Cancer Imaging and Treatment, NIH/NCI, Pl —
`Robert D. Bolskar, 9/1/2008-8/31/2009
`
`Co—|nvestigator, Targeted Potentiation of lmmunotoxin Endosomal Escape, NIH/NCI,
`12/1/2008-12/1/2012
`
`Principal Investigator, 10%, Development of Novel Therapeutics Targeting FN14 in Malignant
`Melanoma, PA—10—067, NIH/NCI, 9/1/2011-8/31/2014, $750,000 ($250,000/year)
`
`Principal Investigator, 10%, Development of Recombinant Human Serine Proteases
`Targeting HER2—Expressing Solid Tumors, PA—10—067, NIH/NCI, 9/1/2011-8/31/2014,
`$750,000 ($250,000/year)
`
`Principal Investigator, 15%, VEGF—based Targeting Approaches to Interrupt Metastatic
`Spread and Tumor/Stromal Interactions, PA—10—067, NIH/NCI, 9/1/2011-8/31/2014, $750,000
`($250,000/year)
`
`Principal Investigator, 0.6 months, rGe|/BLyS Targeting Malignant B—Ce||s for MM, CLL,
`DLBCL and ALL, RP120968, Cancer Prevention & Research Institute of Texas (CPRIT),
`5/1/2012-4/30/2015, $950,001 ($307,731/year)
`
`Co—|nvestigator, The Fn14 Receptor and HER2+ Breast Cancer, NIH R01 , 2/201 1-1/2016,
`$250,000/yr
`
`Co—|nvestigator, Role of Fn14 Signaling in EGFR Tyrosine Kinase |nhibitor—Resistant Lung
`Cancer, N|H—R01, 6/2012-5/2018, $250,000/yr
`
`Co—|nvestigator, The TNFR Family Member Fn14: A New Therapeutic Target for EGFR-
`driven Lung Cancer, Uniting Against Lung Cancer, 8/2012-7/2014, $45,000/yr
`
`Page 5 of 31
`
`PHIGENIX
`
`Exhibit 1032-05
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Co—|nvestigator, Fn14: A New Therapeutic Target for EGFR—Driven Non—Sma|| Cell Lung
`Cancer? ALA Lung Cancer Discovery Award, 11/2012-10/2014, $100,000/yr
`
`Protocols
`Funded
`
`Co—Principa| Investigator, A Phase I, Open—Labe|, Dose Escalation Study of VEGF121/rGEL
`in Solid Tumors, 2005-0756, 2005
`
`Co—Principa| Investigator, A Phase I Dose Finding Study to Evaluate the Pharmacokinetics,
`Toxicity, and Anti—Tumor Activity of scFvMEL/TNF for the Treatment of GP240 Positive
`Malignancies, 2006-0343, 2006
`
`Co—|nvestigator, A Phase 0 PET Imaging Study of 64Cu labeled DOTA—VEGF/rGe| in Patients
`with Solid Tumors. 2014
`
`Unfunded
`N/A
`
`Patents and Technology Licenses
`Patents
`
`Board of Regents, The University of Texas System (Austin, TX), M.G. Rosenblum, J.L.
`Murray, P.J. Kelleher, R.A. Newman, A.R. Khokhar. Monoclonal antibodies binding platinum
`complexes, United States, 5,053,226, 10/1/1991, Issued
`
`Hybritech Incorporated (San Diego, CA), J.M. Frincke, B.W. Unger, K.G. Burnett, E.M. Hersh,
`M.G. Rosenblum, J.U. Gutterman. Antibody compositions oftherapeutic agents having an
`extended serum ha|f—|ife, United States, 5,055,289, 10/8/1991, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum. lmmunotoxins
`directed against CD33 related surface antigens, United States, WO/1993/020848,
`8/4/1993, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, N.J. Donato. Non-
`viral vector, United States, WO/1995/021195, 6/2/1995, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, K.L. Beattie. DNA
`sequences encoding the plant toxin gelonin, United States, 5,624,827, 4/29/1997, Issued
`
`The Research Development Foundation (Carson City, NV), M.G. Rosenblum, W.J. Kohr, B.
`AgganNa|. Protein sequence of the plant toxin gelonin, United States, 5,631,348,
`5/20/1997, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, N.J. Donato. Avidin—
`biotin immunoconjugates, United States, 6,214,974, 4/10/2001, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, N.J. Donato. Anti-
`|gM monoclonal antibodies and methods oftheir use, United States, 6,306,626,
`10/23/2001, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum. lmmunotoxins
`directed against CD33 related surface antigens, United States, 6,599,505, 7/29/2003, Issued
`
`Rosenblum M.G., Novel antibody delivery system for biological response modifiers, United
`States, 10/676725, 10/1/2003, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, R. Dulbecco, W.R.
`Allen. |mmunoConjugates for cancer diagnosis and therapy, United States, 6,669,938,
`12/30/2003, Issued
`
`Research Development Foundation, M.G. Rosenblum, Antibody Delivery System for
`Biological Response Modifiers, United States, 6,750,329, 6/15/2004, Issued
`
`M.G. Rosenblum, Vascular endothelial growth factor fusion constructs and uses thereof,
`United States, 10/919,193, 8/16/2004, Issued
`
`Page 6 of 31
`
`PHIGENIX
`
`Exhibit 1032-06
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Reasearch Development Foundation (Carson City, NV), M.G. Rosenblum, L. Cheung.
`Modified proteins, designer toxins, and methods of making thereof, United States, 7,083,957,
`8/1/2006, Issued
`
`Research Development Foundation (Carson City, NV), M.G Rosenblum, Y. Liu. Therapeutic
`agents comprising pro—apoptotic proteins, United States, 7,101,977, 9/5/2006, Issued
`
`Research Development Foundation (Carson City, NV), Rosenblum M.G, Cheung L., Modified
`proteins, designer toxins, and methods of making thereof, South Africa, 2003/5980,
`1/31/2007, Issued
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, K. Mehta.
`Potentiation of Anti—CD38 lmmunotoxin Cytotoxicity, United States, 7,223,397 (09/226,895),
`5/29/2007, Issued
`
`Research Development Foundation (Carson City, NV), Rosenblum MG, lmmunotoxins
`Directed Against CD33 Related Surface Antigens, United States, 11/868,801,
`10/8/2007, Issued
`
`Research Development Foundation (Carson City, NV), Rosenblum MG, Lyu M—A, Cheung L.
`Therapeutic Agents Comprising Pro—Apoptotic Proteins, United States, 7,371,723,
`5/13/2008, Issued
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum and Yuying
`Liu. Therapeutic Agents Comprising Pro—Apoptotic Proteins, New Zealand, 530582,
`10/9/2008, Issued
`
`Research Development Foundation (Carson City, NV), MG Rosenblum and Lawrence
`Cheung, Modified Proteins, Designer Toxins, and Methods ofMaking Thereof, Australia,
`2002306477, 10/23/2008, Issued
`
`Research Development Foundation (Carson City, NV), Rosenblum MG. Modified Proteins,
`Designer Toxins, and Methods ofMaking Thereof, United States, 11/856,606,
`4/24/2009, Issued
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum and Lawrence
`Cheung. Modified proteins, designer toxins, and methods of making thereof, United States,
`7741278, 6/22/2010, Issued
`
`Research Development Foundation (Carson City, NV), Rosenblum, MG, Targeted
`Polypeptides, United States, 11/345,661, 2/1/2006, Filed
`
`Research Development Foundation (Carson City, NV), Rosenblum MG, Therapeutic Agents
`Targeting IGFBP2, United States, MDA01—102, 5/13/2008, Filed
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum, Compositions
`and Methods of use of Agents Targeting |GFBP—2, United States, 61/108,385,
`10/24/2008, Filed
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum and Lawrence
`Cheung, An lmmunotoxin and Composition Comprising a Recombinant Gelonin Toxin, Korea,
`Republic of, 10—2008—7012188, 11/12/2008, Filed
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum, et al. BLyS
`Fusion Proteins for Targeting BLyS Receptor and Methods for Treatment of B—Ce||
`Proliferative Disorders, United Kingdom, 06734163.6, 12/18/2008, Filed
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum, et al. Modified
`Proteins, Designer Toxins, and Methods of Making Thereof, Japan, 2002—569065,
`12/19/2008, Filed
`
`Page 7 of 31
`
`PHIGENIX
`
`Exhibit 1032-07
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Research Development Foundation (Carson City, N\/), Michael G. Rosenblum and Yuying
`Liu. Therapeutic Agents Comprising Pro—Apoptotic Proteins, United Kingdom, 02763328.8,
`2/8/2009, Filed
`
`Research Development Foundation (Carson City, NV), Rosenblum MG, Liu Y. Therapeutic
`Agents Comprising Pro—Apoptotic Proteins, Israel, 159894, 3/8/2009, Filed
`
`Research Development Foundation (Carson City, NV), Rosenblum MG, Chen X.
`Multimodality Molecular Imaging with Therapeutic Conjugates, United States, 12/402,301,
`4/15/2009, Filed
`
`Research Development Foundation (Carson City, NV), U. Sagman, M.G. Rosenblum, L.
`Wilson, Fullerenes in targeted therapies, United States, Pending, 2003, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, lmmunotoxin as a
`therapeutic agent and uses thereof, United States, 20040013691, 6/12/2003, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, Vascular
`endothelial growth factor fusion constructs and uses thereof, United States, 20040248805,
`5/14/2004, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum. Antibody
`conjugates for treatment of neoplastic disease, United States, 20050214307,
`8/26/2004, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, L.K. Shawver.
`lmmunotoxins directed against c—erbB—2(HER—2/neu) related surface antigens, United States,
`20050163774, 10/13/2004, Pending
`
`Research Development Foundation (Carson City, NV), R. Lebovitz, M.G. Rosenblum,
`Substituted fullerenes and their use as inhibitors of cell death, United States, 20060247152,
`5/2/2005, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, A.D. Ellington.
`Targeted chimeric molecules for cancer therapy, United States, 20060263368,
`1/10/2006, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, L. Cheung, M.A.
`Lyu. Targeted polypeptides, United States, 20060171919, 2/1/2006, Pending
`
`Research Development Foundation (Carson City, NV), M.G. Rosenblum, P.A. Campochiaro,
`Vascular targeting of ocular neovascularization, United States, 20070025957,
`4/28/2006, Pending
`
`Reseach Development Foundation (Carson City, NV), Y. Liu, M.G. Rosenblum. Cell targeted
`IKB and methods for the use thereof, United States, 20070202593 (11/679,630),
`2/27/2007, Pending
`
`Research Development Foundation (Carson City, N\/)Michae| G. Rosenblum and Lawrence
`Cheung. Modified Proteins, Designer Toxins, and Methods of Making Thereof, Israel,
`157228, 1/29/2009, Pending
`
`Research Development Foundation (Carson City, NV), Michael G. Rosenblum, Lawrence
`Cheung, Khalid Mohamedali, Designer Granzymes, USPTO filed 2013.
`
`Technology Licenses
`Biocad, |nc— License to VEGF/rGe| related technology, 2012- Present
`
`Grant Reviewer/Service on Study Sections
`US Army Breast Cancer Program, DOD, Member, Clinical and Experimental Therapeutics
`Review Panel (CET—2), 1995-1996
`
`Page 8 of 31
`
`PHIGENIX
`
`Exhibit 1032-08
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`Experimental Therapeutics Study Section, DOD, Member, 2001-2003
`
`Cancer Study Section, Tobacco—re|ated disease research program, for the States of California
`and Colorado, Member, 2001-2004
`
`Study Section, Cancer lmmunobiology and lmmunotherapy, NIH, Member, 2007-2009
`
`Study Section, SBIR ZRG1—X(14), NIH, Member, 2009-2011
`
`PUBLICATIONS
`
`Peer-Reviewed Original Research Articles
`1. Cargill RL, Rosenblum MG. Synthesis of the housefly sex attractant. J Org Chem
`37(24):3971, 12/1972.
`2. Gale GR, Rosenblum MG, Atkins LM, Walker EM, Smith AB, Meischen SJ. Antitumor action
`of cis—dich|orobis(methy|amine)p|atinum(|I). J Natl Cancer Inst 51(4):1227—34, 10/1973.
`3. Meischen SJ, Gale GR, Lake LM, Frangakis CJ, Rosenblum MG, Walker EM, Atkins LM,
`Smith AB. Antileukemic properties of organoplatinum complexes. J Natl Cancer Inst
`57(4):841—5, 10/1976.
`4. Rosenblum MG, Russell DH. Conjugation of radiolabeled polyamines in the rat. Cancer Res
`37(1):47—51, 1/1977.
`5. Rosenblum MG, Durie BG, Beckerman RC, Taussig LM, Russell DH. Cystic fibrosis:
`decreased conjugation and excretion of [14C] spermidine. Science 200(4349):1496—7,
`6/1978.
`
`6. Rosenblum MG, Durie BG, Salmon SE, Russell DH. Metabolism of [14C] spermidine and
`[14C] putrescine in normal volunteers and in cancer patients. Cancer Res 38(10):3161—3,
`10/1978.
`
`7. Russell DH, Rosenblum MG, Beckerman RC, Durie BG, Taussig LM, Barnett DR. Altered
`polyamine metabolism in cystic fibrosis. Pediatr Res 13(10):1137—40, 10/1979.
`8. Rosenblum MG, Loo TL. High—performance liquid chromatographic analysis ofthe anticancer
`agent methylglyoxal bis(guany|hydrazone) (MGBG, NSC—32946) in biological fluids. J
`Chromatogr183(3):363—6, 9/1980.
`9. Rosenblum MG, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL. Penetration of
`methylglyoxal bis(guany|hydrazone) into intracerebral tumors in humans. Cancer Res
`41 (2):459—62, 2/1981.
`10. Rosenblum MG, Keating MJ, Yap BS, Loo TL. Pharmacokinetics of [14C]methy|g|yoxa|—bis—
`guanylhydrazone) in patients with leukemia. Cancer Res 41 (5)21 748-50, 5/1981.
`11. Loo TL, Lu K, Benvenuto JA, Rosenblum MG. Disposition and metabolism ofthiopurines III.
`beta—2'—Deoxythioguanosine and 6—thioguanine in the dog. Cancer Chemother Pharmacol
`6(2):131—6, 1981.
`12. Stewart DJ, Rosenblum MG, Luna M, Loo TL. Disposition of methylglyoxal
`bis(guany|hydrazone) (MGBG, NSC—32946) in man. Cancer Chemother Pharmacol 7(1):31—5,
`1981.
`
`13. Lu K, Rosenblum MG, Loo TL. Effects ofendotoxin on the pharmacology of antineoplastic
`agents. Cancer Chemother Pharmacol 5(4):227—31, 1981.
`14. Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG, Loo TL. Pharmacokinetics and
`metabolism of beta—2'—deoxythioguanosine and 6—thioguanine in man. Cancer Chemother
`Pharmacol 8(1):119—23, 4/1982.
`15. Grossie VB, Rosenblum MG, Loo TL. Combination chemotherapy with cyclophosphamide
`and ftorafur against advanced L1210 murine leukemia. Cancer Treat Rep 66(8):1631—4,
`8/1982.
`
`16. Loo TL, Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG. Pharmacokinetics and
`metabolism of B2‘ deoxythioguanosine and 6—thioguanine in man. Cancer Chemo and
`Pharmacol 8(1):119—123, 1982.
`17. Rosenblum MG, Hersh EM, Loo TL. Determination of the biological response modifier MVE—2
`(AD—022) in biological fluids by high—performance liquid chromatography. J Chromatogr
`272(1):200—4, 1/1983.
`
`Page 9 of 31
`
`PHIGENIX
`
`Exhibit 1032-09
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`18.
`
`19.
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`Hersh EM, Reuben JM, Bogerd H, Rosenblum M, Bielski M, Mansell PW, Rios A, Newell GR,
`Sonnenfeld G. Effect of the recreational agent isobutyl nitrite on human peripheral blood
`leukocytes and on in vitro interferon production. Cancer Res 43:1365—71, 3/1983.
`Rios A, Rosenblum M, Powell M, Hersh E. Phase I study of MVE—2 therapy in human cancer.
`Cancer Treat Rep 67:239—43, 3/1983.
`McCullough JL, Weinstein GD, Rosenblum MG, Jenkins JJ. Percutaneous penetration of
`methylglyoxal bis(guany|hydrazone): effects on hairless mouse epidermis in vivo. J Invest
`Dermatol 81(5):388—92, 11/1983.
`Lopez—Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by
`liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans.
`Cancer Drug Deliv 1(3):199—205, 1/1984.
`Rosenblum MG, Hortobagyi GN, Landers DW, Hersh EM. Analysis of the antitumor agent
`Bay I 7433 (copovithane) in plasma and urine by high performance liquid chromatography. J
`Liquid Chromatography 7(1):159—166, 1/1984.
`Lopez—Berestein G, Kasi L, Rosenblum MG, Haynie T, Jahns M, Glenn H, Mehta R, Mavligit
`GM, Hersh EM. Clinical pharmacology of 99mTc—|abe|ed liposomes in patients with cancer.
`Cancer Res 44(1):375—8, 1/1984.
`Kasi LP, Lopez—Berestein G, Mehta K, Rosenblum M, Glenn HJ, Haynie TP, Mavligit G,
`Hersh EM. Distribution and pharmacology ofintravenous 99mTc—|abe|ed multilamellar
`liposomes in rats and mice. Int J Nucl Med Biol 11(1):35—7, 1/1984.
`Rosenblum MG, Gutterman JU. Synergistic antiproliferative activity of leukocyte interferon in
`combination with aIpha—dif|uoromethy|ornithine against human cells in culture. Cancer Res
`44(6):2339—40, 6/1984.
`Lotzova E, Savary CA, Hersh EM, Khan AA, Rosenblum MG. Depression of murine natural
`killer cell cytotoxicity by isobutyl nitrite. Cancer lmmunol lmmunother 17(2):130—4, 8/1984.
`Gutterman JU, Rosenblum MG, Rios A, Fritsche HA, Quesada JR. Pharmacokinetic study of
`partially pure gamma—interferon in cancer patients. Cancer Res 44(9):4164—71, 9/1984.
`Oh SH, Conley SB, Rose GM, Rosenblum M, Kohl S, Pickering LK. Fungal peritonitis in
`children undergoing peritoneal dialysis. Pediatr Infect Dis 4(1):62—6, 1/1985.
`Lopez—Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG,
`Mehta R, Luna M, Hersh EM. Liposomal amphotericin B for the treatment of systemic fungal
`infections in patients with cancer: a preliminary study. J Infect Dis 151(4):704—10, 4/1985.
`Rosenblum MG, Murray JL, Haynie TP, Glenn HJ, Jahns MF, Benjamin RS, Frincke JM,
`Carlo DJ, Hersh EM. Pharmacokinetics of 111|n—|abe|ed anti—p97 monoclonal antibody in
`patients with metastatic malignant melanoma. Cancer Res 45(5):2382—6, 5/1985.
`Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager CE, Haynie TP, Jahns MF,
`Glenn HJ, Lamki L, Benjamin RS. Radioimmunoimaging in malignant melanoma with 111|n—
`labeled monoclonal antibody 96.5. Cancer Res 45(5):2376—81, 5/1985.
`Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of
`human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res
`45(6):2421—4, 6/1985.
`Kurzrock R, Rosenblum MG, ShenNin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU.
`Pharmacokinetics, sing|e—dose tolerance, and biological activity of recombinant gamma-
`interferon in cancer patients. Cancer Res 45(6):2866—72, 6/1985.
`Krizan Z, Murray JL, Hersh EM, Rosenblum MG, Glenn HJ, Gschwind CR, Carlo DJ.
`Increased labeling of human melanoma cells in vitro using combinations of monoclonal
`antibodies recognizing separate cell surface antigenic determinants. Cancer Res
`45(10):4904—9, 10/1985.
`Rosenblum MG, Rios A, Gutterman JU. Activation of 2',5'—o|igoadeny|ate synthetase and B-2
`microglobulin in cancer patients treated with partially pure gamma interferon: dependence of
`biological effect on administration route. Cancer Chemother Pharmacol 16(3):273—6, 4/1986.
`Hortobagyi GN, Hersh EM, Papadopoulos NE, Frye D, Rios A, Reuben JM, Plager C,
`Rosenblum MG, Quesada J. Initial clinical studies with copovithane. J Biol Response Mod
`5(4):319—29, 8/1986.
`Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. In vivo
`sensitivity and resistance of chronic myelogenous leukemia cells to a|pha—interferon:
`
`Page 10 of31
`
`PHIGENIX
`
`Exhibit 1032-10
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`51.
`
`52.
`
`53.
`
`54.
`
`correlation with receptor binding and induction of 2',5'—o|igoadeny|ate synthetase. Cancer Res
`46(9):4848—52, 9/1986.
`Rosenblum MG, Cheung L. A high performance liquid chromatographic method for analysis
`of synthetic, mismatched double—stranded RNA (AMPLIGEN) in plasma. J Liquid
`Chromatography 9(13):2869—2877, 10/1986.
`Kurzrock R, Rosenblum MG, Quesada JR, ShenNin SA, Itri LM, Gutterman JU. Phase I study
`ofa combination of recombinant interferon—a|pha and recombinant interferon—gamma in
`cancer patients. J Clin Oncol 4(11):1677—83, 11/1986.
`Rosenblum MG, Rios AM, Hersh EM. Clinical pharmacology ofthe biological response
`modifier maleic anhydride divinyl ether copolymer (MVE—2). Cancer Chemother Pharmacol
`18(3):243—6, 12/1986.
`Rosenblum MG, Hortobagyi GN. Pharmacokinetics and tissue disposition ofthe biological
`response modifier BAY i 7433 (copovithane) in patients with cancer. Cancer Chemother
`Pharmacol 18(3):247—51, 12/1986.
`Kurzrock R, Quesada JR, Rosenblum MG, ShenNin SA, Gutterman JU. Phase I study ofi.v.
`administered recombinant gamma interferon in cancer patients. Cancer Treat Rep
`70(12):1357—64, 12/1986.
`Murray JL, Rosenblum MG, Lamki L, Glenn HJ, Krizan Z, Hersh EM, Plager CE,
`Bartholomew RM, Unger MW, Carlo DJ. Clinical parameters related to optimal tumor
`localization ofindium—111—|abe|ed mouse antimelanoma monoclonal antibody ZME—018. J
`Nucl Med 28(1):25—33, 1/1987.
`Murray JL, Rosenblum MG, Lamki L, Haynie TP, Glenn HJ, Plager CE, Unger MW, Carlo DJ,
`Hersh EM. Radioimmunoimaging in malignant melanoma patients with the use of indium—1 1 1-
`Iabeled antimelanoma monoclonal antibody (ZME—018) to high—mo|ecu|ar—weight antigen. NCI
`Monographs 3:3—9, 1/1987.
`Babaian RJ, Murray JL, Lamki LM, Haynie TP, Hersh EM, Rosenblum MG, Glenn HJ, Unger
`MW, Carlo DJ, von Eschenbach AC. Radioimmunological imaging of metastatic prostatic
`cancer with 111indium—|abe|ed monoclonal antibody PAY 276. J Urol 137(3):439—43, 3/1987.
`Talpaz M, Rosenblum MG, Kurzrock R, Reuben J, Kantarjian H, Gutterman J. Clinical and
`laboratory changes induced by alpha interferon in chronic lymphocytic |eukemia——a pilot
`study. Am J Hematol 24(4):341—50, 4/1987.
`Blick M, Sherwin SA, Rosenblum MG, Gutterman J. Phase I study of recombinant tumor
`necrosis factor in cancer patients. Cancer Res 47(11):2986—9, 6/1987.
`Rosenblum MG, Murray JL, Lamki L, David G, Carlo D. Comparative clinical pharmacology of
`[111|n]—|abe|ed murine monoclonal antibodies. Cancer Chemother Pharmacol 20(1):41—7,
`8/1987.
`
`Yung WK, Steck PA, Kelleher PJ, Moser RP, Rosenblum MG. Growth inhibitory effect of
`recombinant alpha and beta interferon on human glioma cells. J Neurooncol 5(4):323—30,
`12/1987.
`
`McCredie KB, Talpaz M, Kantarjian H, Rosenblum MG, Keating M, Gutterman J. Biologic
`agents for the management of hematological disorders: chronic myeloid leukemia. Haematol
`Blood Transfus 31 :120—2, 1987.
`Rosenblum MG, Donato NJ, Gutterman JU. Characterization of human recombinant tumor
`necrosis factor—alpha antiproliferative effects on human cells in culture. Lymphokine Res
`7(2):107—17, 1/1988.
`Murray JL, Stuckey SE, Pillow JK, Rosenblum MG, Gutterman JU. Differential in vitro effects
`of recombinant a|pha—interferon and recombinant gamma—interferon alone or in combination
`on the expression of me|anoma—associated surface antigens. J Biol Response Mod 7(2):152—
`61, 4/1988.
`Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU. |nterferon—induced changes
`in pharmacokinetics and tumor uptake of 111|n—|abe|ed antimelanoma antibody 96.5 in
`melanoma patients. J Natl Cancer Inst 80(3):160—5, 4/1988.
`Rosenblum MG, Cheung L, Kessler D. Differential activity of the 30—kD and the 100—kD forms
`of 2'—5'An synthetase induced by recombinant human interferon—a|pha and interferon—gamma.
`J Interferon Res 8(3):275—82, 6/1988.
`
`Page 11 of31
`
`PHIGENIX
`
`Exhibit 1032-11
`
`

`
`Michael G. Rosenblum, Ph.D.
`
`55.
`
`56.
`
`57.
`
`58.
`
`59.
`
`60.
`
`61.
`
`62.
`
`63.
`
`64.
`
`65.
`
`66.
`
`67.
`
`68.
`
`69.
`
`70.
`
`71.
`
`Neidhart JA, Schmidt S, Rosenblum MG, Raber MN, Quesada JR, Alton NK, Downing M.
`Phase I study of recombinant methionyl human consensus interferon (r—metHu|FN—Con1). J
`Biol Response Mod 7(3):240—8, 6/1988.
`Lamki LM, Murray JL, Rosenblum MG, Patt YZ, Babaian R, Unger MW. Effect of unlabelled
`monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb). Nucl Med
`Commun 9(8):553—64, 8/1988.
`Murray JL, Lamki LM, Shanken LJ, Blake ME, Plager CE, Benjamin RS, Schweighardt S,
`Unger MW, Rosenblum MG. lmmunospecific saturable clearance mechanisms for indium-
`111—|abe|ed anti—me|anoma monoclonal antibody 96.5 in humans. Cancer Res 48(15):4417—
`22, 8/1988.
`Patt YZ, Lamki LM,